Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
Inclusion Criteria:
For inclusion in the cohort analysis, patients must have data in the EBMT registry that
meet the following criteria:
- Adults diagnosed with lymphoma or multiple myeloma (MM)
- Received first autologous transplants of peripheral blood (PB) non ex-vivo
manipulated stem cells in the time period listed above using cells mobilised with
one of the following regimens:
- plerixafor plus granulocyte colony stimulating factor (G-CSF)
- plerixafor plus G-CSF plus chemotherapy
- G-CSF alone or
- G-CSF plus chemotherapy
Note: Patients included in the plerixafor groups will be those treated according to the
label
- Provision of informed consent (i.e., all patients with data in the EBMT registry will
have signed consent at the time of transplantation for the potential use of their
data for analysis)
Exclusion Criteria:
- Patients treated with plerixafor NOT according to the European Union (EU) label.
- Patients whose graft product underwent ex vivo manipulation will be excluded from
analysis